background
patient
preexist
cirrhosi
consid
increas
risk
sever
coronaviru
diseas
clinic
cours
patient
yet
report
studi
aim
provid
detail
report
clinic
characterist
outcom
among
patient
preexist
cirrhosi
method
retrospect
multicent
cohort
studi
consecut
includ
adult
inpati
laboratoryconfirm
preexist
cirrhosi
discharg
die
march
design
hospit
china
demograph
clinic
laboratori
radiograph
find
admiss
treatment
complic
hospit
clinic
outcom
collect
compar
survivor
nonsurvivor
find
twentyon
patient
includ
consecut
studi
cure
die
hospit
seventeen
patient
compens
cirrhosi
hepat
b
viru
infect
common
etiolog
lymphocyt
platelet
count
lower
direct
bilirubin
level
higher
patient
die
surviv
p
respect
acut
respiratori
distress
syndrom
secondari
infect
frequent
observ
complic
one
patient
develop
acut
chronic
liver
failur
nonsurvivor
patient
develop
acut
respiratori
distress
syndrom
patient
progress
multipl
organ
dysfunct
syndrom
interpret
lower
lymphocyt
platelet
count
higher
direct
bilirubin
level
might
repres
poor
prognost
indic
patient
preexist
cirrhosi
coronaviru
diseas
caus
sever
acut
respiratori
syndrom
becom
global
challeng
sinc
decemb
concern
rais
recent
patient
preexist
cirrhosi
known
compromis
immun
function
poorer
outcom
acut
respiratori
distress
syndrom
ard
patient
without
cirrhosi
howev
remain
unclear
infect
affect
liver
modifi
clinic
cours
cirrhosi
whether
cirrhosi
consid
signific
risk
factor
advers
outcom
previou
studi
proport
patient
preexist
liver
condit
includ
hepat
viru
infect
abnorm
liver
function
chronic
liver
diseas
among
infect
patient
rang
one
half
patient
admit
hospit
infect
may
elev
liver
function
test
emerg
liver
function
abnorm
admiss
associ
longer
hospit
stay
far
studi
report
clinic
featur
risk
factor
inhospit
death
patient
preexist
cirrhosi
aim
multicent
studi
describ
demograph
characterist
coexist
condit
laboratori
imag
find
outcom
among
patient
preexist
cirrhosi
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
retrospect
multicentr
studi
covidcirrhosischess
clinicaltrialsgov
includ
consecut
patient
laboratoryconfirm
preexist
cirrhosi
design
hospit
china
decemb
march
confirm
case
defin
posit
result
highthroughput
sequenc
realtim
reversetranscriptas
polymerasechainreact
assay
nasopharyng
swab
specimen
specif
igm
igg
serum
specif
igg
titrat
least
higher
recoveri
stage
acut
stage
cirrhosi
diagnos
base
previou
liver
biopsi
result
andor
clinic
find
includ
histori
chronic
liver
diseas
well
document
complic
chronic
liver
diseas
ie
ascit
varic
hepat
encephalopathi
andor
imag
consist
cirrhosi
pregnant
women
children
age
year
exclud
studi
approv
institut
ethic
commiss
first
hospit
lanzhou
univers
inform
consent
waiv
research
analyz
deidentifi
data
demograph
data
comorbid
histori
cirrhosi
onset
symptom
sign
laboratori
find
chest
ct
result
admiss
collect
childpugh
class
model
endstag
liver
diseas
meld
score
assess
base
laboratori
find
admiss
treatment
regimen
complic
clinic
outcom
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
hospit
also
collect
accord
clinic
outcom
patient
divid
two
group
survivor
group
nonsurvivor
group
exposur
histori
defin
exposur
peopl
confirm
infect
wuhan
citi
china
leukopenia
defin
leukocyt
count
less
l
lymphocytopenia
defin
lymphocyt
count
less
l
thrombocytopenia
defin
platelet
count
less
l
hypoproteinemia
defin
serum
albumin
level
less
hyperbilirubinemia
defin
total
bilirubin
level
higher
acuteonchron
liver
failur
aclf
defin
accord
european
associ
studi
liver
criteria
ard
diagnos
accord
berlin
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
categor
variabl
report
count
percentag
continu
variabl
present
median
interquartil
rang
mannwhitney
u
test
fisher
exact
test
use
compar
differ
survivor
nonsurvivor
appropri
twosid
pvalu
less
consid
statist
signific
data
analyz
spss
version
window
spss
inc
chicago
il
usa
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
twentyon
patient
preexist
cirrhosi
identifi
includ
final
analysi
median
age
patient
year
rang
year
male
tabl
patient
compens
cirrhosi
childpugh
class
b
c
patient
respect
median
meld
score
rang
twelv
patient
chronic
hepat
b
includ
also
hepat
c
viru
coinfect
alcohol
abus
schistosomiasi
respect
comorbid
cirrhosi
present
patient
hypertens
coronari
heart
diseas
common
comorbid
follow
type
diabet
malign
median
interv
onset
ill
admiss
day
rang
day
common
symptom
admiss
fever
cough
follow
short
breath
sputum
product
signific
differ
survivor
nonsurvivor
age
sex
comorbid
etiolog
cirrhosi
stage
cirrhosi
compens
versu
decompens
childpugh
class
meld
score
interv
onset
admiss
onset
symptom
leukopenia
lymphopenia
thrombocytopenia
occur
patient
respect
tabl
hypoproteinemia
hyperbilirubinemia
prolong
prothrombin
time
occur
patient
respect
elev
aspart
transaminas
alanin
aminotransferas
gammaglutamyl
transferas
level
present
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
patient
respect
nearli
patient
least
one
typic
sign
infect
chest
ct
includ
groundglass
opac
consolid
bilater
pulmonari
infiltr
figur
show
repres
chest
ct
imag
abdomin
imag
cirrhosi
survivor
nonsurvivor
group
patient
die
lower
total
lymphocyt
platelet
count
higher
direct
bilirubin
level
patient
surviv
p
respect
tabl
treatment
complic
occur
hospit
summar
tabl
five
patient
transfer
intens
care
unit
includ
four
patient
nonsurvivor
group
p
use
system
corticosteroid
p
noninvas
ventil
p
invas
mechan
ventil
p
continu
renal
replac
therapi
p
extracorpor
membran
oxygen
p
differ
significantli
nonsurvivor
survivor
overal
patient
receiv
antivir
treatment
among
arbidol
monotherapi
lopinavirritonavir
plu
interferon
combin
therapi
oseltamivir
monotherapi
given
seven
five
three
patient
respect
two
patient
experienc
switch
antivir
regimen
one
lopinavirritonavir
plu
arbidol
combin
therapi
interferon
monotherapi
one
arbidol
monotherapi
lopinavirritonavir
plu
interferon
combin
therapi
secondari
infect
ard
frequent
observ
complic
follow
ascit
one
patient
develop
aclf
frequenc
ard
gastrointestin
bleed
higher
nonsurvivor
survivor
vs
p
vs
p
respect
among
five
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
patient
die
develop
ard
two
progress
multipl
organ
dysfunct
syndrom
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
retrospect
multicent
studi
covidcirrhosischess
report
demograph
characterist
coexist
condit
laboratori
imag
find
outcom
among
patient
preexist
cirrhosi
caus
death
patient
due
progress
liver
diseas
rather
pulmonari
diseas
lower
lymphocyt
platelet
count
higher
direct
bilirubin
level
observ
patient
surviv
compar
die
cohort
patient
preexist
cirrhosi
found
fever
cough
common
symptom
admiss
patient
comorbid
cirrhosi
find
similar
previou
studi
among
gener
popul
accord
china
center
diseas
control
prevent
report
laboratoryconfirm
case
death
mainli
observ
among
patient
older
age
andor
preexist
comorbid
condit
includ
cardiovascular
diseas
diabet
chronic
respiratori
diseas
hypertens
cancer
itali
besid
mention
factor
male
patient
also
increas
risk
death
reveal
report
first
month
document
case
far
studi
report
risk
factor
death
patient
preexist
cirrhosi
analysi
indic
higher
mortal
includ
patient
older
age
male
sex
preexist
comorbid
might
due
narrow
spectrum
studi
popul
limit
sampl
size
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
liver
play
import
role
adapt
innat
immun
respons
enrich
lymphocyt
includ
b
lymphocyt
natur
killer
cell
addit
liver
central
regul
number
circul
platelet
via
thrombopoietin
product
clearanc
age
platelet
thu
patient
cirrhosi
like
lymphopenia
thrombocytopenia
diseas
progress
becom
promin
studi
frequenc
lymphopenia
thrombocytopenia
high
nonsurvivor
group
decompens
cirrhosi
addit
lower
lymphocyt
platelet
count
admiss
observ
nonsurvivor
compar
survivor
find
also
demonstr
previou
studi
gener
popul
metaanalysi
includ
studi
patient
show
lymphopenia
common
laboratori
find
consist
respiratori
viru
infect
anoth
metaanalysi
studi
effect
platelet
count
prognosi
show
compar
patient
surviv
low
platelet
count
associ
fivefold
increas
risk
sever
direct
bilirubin
also
observ
higher
nonsurvivor
survivor
studi
suggest
potenti
advers
effect
liver
function
set
find
underscor
patient
preexist
cirrhosi
decreas
lymphocyt
platelet
count
increas
direct
bilirubin
monitor
may
indic
poorer
prognosi
recogn
limit
current
studi
first
sampl
size
small
limit
analysi
predict
factor
mortal
generaliz
result
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
studi
larg
sampl
size
prospect
design
need
better
describ
clinic
cours
patient
preexist
cirrhosi
determin
risk
factor
poor
outcom
set
secondli
major
patient
studi
underli
hepat
b
virusrel
cirrhosi
howev
date
evid
suggest
patient
stabl
chronic
liver
diseas
due
viral
hepat
increas
suscept
infect
absenc
liver
biopsi
know
whether
infect
effect
liver
histopatholog
studi
popul
lastli
studi
includ
patient
chines
medic
institut
whether
data
generaliz
patent
part
world
remain
unknown
conclus
report
demograph
characterist
coexist
condit
laboratori
imag
find
outcom
among
patient
preexist
cirrhosi
appear
caus
death
patient
due
progress
liver
diseas
ie
develop
aclf
rather
pulmonari
diseas
present
lower
lymphocyt
platelet
count
higher
direct
bilirubin
level
may
associ
higher
risk
death
declar
compet
interest
relat
paper
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
lymphocyt
l
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
